German CDMO Rentschler expands biologics capacity with deal for Shire site

German CDMO, which is looking to grow its manufacturing network, is adding a site in the U.S. (Rentschler)

Shire started looking for a buyer for a small biologics manufacturing site in Massachusetts shortly after its buyout of Baxalta two years ago. It has finally made a deal.

German CDMO Rentschler Biopharma, which focuses on biologics development and manufacturing, says it has an agreement to buy the former Baxalta manufacturing site in Milford, Massachusetts. It will be Rentschler's first move into the U.S. 

The 100,000-square-foot facility has about 70 employees and Rentschler spokesperson said they have all be offered jobs. The family-owned Rentschler, which currently has about 850 workers, said it will continue to manufacture products for Shire after the deal closes. Terms of the deal were not disclosed.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

RELATED: German CDMO Rentschler expands biologics production capacity

Rentschler, which is looking to expand globally, two years ago added a new facility to its site in Laupheim, Germany, to expand its  capacity, saying it recognized the growing demand for biologics. It invested about  €24 million to add two 3,000-liter stainless steel bioreactors, more than doubling its capacity, and had plans to add 200 jobs.

The sale by Shire comes just after Japan’s Takeda announced it is buying the rare disease drug maker for $58 billion, a deal that is expected to result in more consolidation as Takeda looks for extra cash flow to pay for the deal.

Suggested Articles

FDA officials say Novartis took too long to launch a formal probe into allegations of Zolgensma data manipulation.

Should Johnson & Johnson owe billions to fix Oklahoma's opioid crisis? After weeks of trial testimony, a judge will have his say Monday afternoon.

After Endo and Allergan agreed to settle with two Ohio counties on opioid charges this week, the state’s AG has a message: You’re not off the hook.